Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Molecular impact of the M184V mutation in human immunodeficiency virus type 1 reverse transcriptase.

Literature DB >> 14576091

Molecular impact of the M184V mutation in human immunodeficiency virus type 1 reverse transcriptase.

Karidia Diallo¹, Matthias Götte, M A Wainberg.

Abstract

Entities: Mutation Species

Mesh：

Substances：

Year: 2003 PMID： 14576091 PMCID： PMC253767 DOI： 10.1128/AAC.47.11.3377-3383.2003

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

× No keyword cloud information.

69 in total

1. The M184V mutation in HIV-1 reverse transcriptase reduces the restoration of wild-type replication by attenuated viruses.

Authors: Xin Wei; Chen Liang; Matthias Götte; Mark A Wainberg
Journal: AIDS Date: 2002-12-06 Impact factor: 4.177

2. Mutational sensitivity patterns define critical residues in the palm subdomain of the reverse transcriptase of human immunodeficiency virus type 1.

Authors: S F Chao; V L Chan; P Juranka; A H Kaplan; R Swanstrom; C A Hutchison
Journal: Nucleic Acids Res Date: 1995-03-11 Impact factor: 16.971

3. Fidelity of two retroviral reverse transcriptases during DNA-dependent DNA synthesis in vitro.

Authors: J D Roberts; B D Preston; L A Johnston; A Soni; L A Loeb; T A Kunkel
Journal: Mol Cell Biol Date: 1989-02 Impact factor: 4.272

4. Analysis of mutations at position 184 in reverse transcriptase of human immunodeficiency virus type 1.

Authors: P L Boyer; S H Hughes
Journal: Antimicrob Agents Chemother Date: 1995-07 Impact factor: 5.191

5. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides.

Authors: R F Schinazi; R M Lloyd; M H Nguyen; D L Cannon; A McMillan; N Ilksoy; C K Chu; D C Liotta; H Z Bazmi; J W Mellors
Journal: Antimicrob Agents Chemother Date: 1993-04 Impact factor: 5.191

6. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase.

Authors: L M Mansky; H M Temin
Journal: J Virol Date: 1995-08 Impact factor: 5.103

7. Mechanistic studies to understand the progressive development of resistance in human immunodeficiency virus type 1 reverse transcriptase to abacavir.

Authors: Adrian S Ray; Aravind Basavapathruni; Karen S Anderson
Journal: J Biol Chem Date: 2002-08-09 Impact factor: 5.157

8. In vitro enzymatic activity of human immunodeficiency virus type 1 reverse transcriptase mutants in the highly conserved YMDD amino acid motif correlates with the infectious potential of the proviral genome.

Authors: J K Wakefield; S A Jablonski; C D Morrow
Journal: J Virol Date: 1992-11 Impact factor: 5.103

9. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance.

Authors: H Huang; R Chopra; G L Verdine; S C Harrison
Journal: Science Date: 1998-11-27 Impact factor: 47.728

10. In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA.

Authors: M A Wainberg; M D Miller; Y Quan; H Salomon; A S Mulato; P D Lamy; N A Margot; K E Anton; J M Cherrington
Journal: Antivir Ther Date: 1999

28 in total

Review 1. HIV-1 drug resistance mutations: an updated framework for the second decade of HAART.

Authors: Robert W Shafer; Jonathan M Schapiro
Journal: AIDS Rev Date: 2008 Apr-Jun Impact factor: 2.500

2. In vitro cross-resistance profile of nucleoside reverse transcriptase inhibitor (NRTI) BMS-986001 against known NRTI resistance mutations.

Authors: Zhufang Li; Brian Terry; William Olds; Tricia Protack; Carol Deminie; Beatrice Minassian; Beata Nowicka-Sans; Yongnian Sun; Ira Dicker; Carey Hwang; Max Lataillade; George J Hanna; Mark Krystal
Journal: Antimicrob Agents Chemother Date: 2013-08-26 Impact factor: 5.191

3. Antiviral Activity of Tenofovir Alafenamide against HIV-1 with Thymidine Analog-Associated Mutations and M184V.

Authors: Nicolas Margot; Renee Ram; Michael Abram; Richard Haubrich; Christian Callebaut
Journal: Antimicrob Agents Chemother Date: 2020-03-24 Impact factor: 5.191

4. Engineering of a chimeric RB69 DNA polymerase sensitive to drugs targeting the cytomegalovirus enzyme.

Authors: Egor P Tchesnokov; Aleksandr Obikhod; Raymond F Schinazi; Matthias Götte
Journal: J Biol Chem Date: 2009-07-21 Impact factor: 5.157

5. Subunit-selective mutational analysis and tissue culture evaluations of the interactions of the E138K and M184I mutations in HIV-1 reverse transcriptase.

Authors: Hong-Tao Xu; Maureen Oliveira; Peter K Quashie; Matthew McCallum; Yingshan Han; Yudong Quan; Bluma G Brenner; Mark A Wainberg
Journal: J Virol Date: 2012-05-23 Impact factor: 5.103

6. Molecular Epidemiology of HIV-1 Virus in Puerto Rico: Novel Cases of HIV-1 Subtype C, D, and CRF-24BG.

Authors: Pablo López; Omayra De Jesús; Yasuhiro Yamamura; Nayra Rodríguez; Andrea Arias; Raphael Sánchez; Yadira Rodríguez; Vivian Tamayo-Agrait; Wilfredo Cuevas; Vanessa Rivera-Amill
Journal: AIDS Res Hum Retroviruses Date: 2018-05-23 Impact factor: 2.205

7. Effect of mutations at position E138 in HIV-1 reverse transcriptase and their interactions with the M184I mutation on defining patterns of resistance to nonnucleoside reverse transcriptase inhibitors rilpivirine and etravirine.

Authors: Hong-Tao Xu; Susan P Colby-Germinario; Eugene L Asahchop; Maureen Oliveira; Matthew McCallum; Susan M Schader; Yingshan Han; Yudong Quan; Stefan G Sarafianos; Mark A Wainberg
Journal: Antimicrob Agents Chemother Date: 2013-04-22 Impact factor: 5.191